5.79
-0.51(-8.10%)
Currency In USD
| Previous Close | 6.3 |
| Open | 6.2 |
| Day High | 6.39 |
| Day Low | 5.67 |
| 52-Week High | 9.82 |
| 52-Week Low | 3.28 |
| Volume | 71,463 |
| Average Volume | 253,685 |
| Market Cap | 54.95M |
| PE | -2.02 |
| EPS | -2.87 |
| Moving Average 50 Days | 7.67 |
| Moving Average 200 Days | 5.99 |
| Change | -0.51 |
If you invested $1000 in Verrica Pharmaceuticals Inc. (VRCA) since IPO date, it would be worth $330.86 as of February 21, 2026 at a share price of $5.79. Whereas If you bought $1000 worth of Verrica Pharmaceuticals Inc. (VRCA) shares 5 years ago, it would be worth $394.15 as of February 21, 2026 at a share price of $5.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced t
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced t
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for a